Aminophylline

Evidence Level: L4

Predicted Indications: 9

Aminophylline

Pharmacist Assessment Report

Aminophylline: From an Unspecified Original Indication to Migraine Disorder

One-Sentence Summary

Aminophylline is a methylxanthine drug (an adenosine receptor antagonist and phosphodiesterase inhibitor) that is currently marketed in Canada as an injectable. The TxGNN model predicts it may be effective for migraine disorder, but there are no registered clinical trials and only 4 publications (one narrative review, the rest case reports or older articles), so this remains a research question rather than a validated direction.

Quick Overview

Item	Content
Original Indication	Not specified in the Canadian licence data
Predicted New Indication	Migraine disorder
TxGNN Prediction Score	0.9988
Evidence Level	L4
Canada Market Status	Marketed (marketed DINs: 1 of 1)
Number of DINs	1 (marketed: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data was not available in the data compiled for this report. Based on general pharmacology, aminophylline is a non-selective adenosine receptor antagonist and phosphodiesterase inhibitor. It is widely known for bronchodilation and smooth muscle relaxation.

Adenosine signalling has been implicated in migraine and trigeminovascular activation. A 2023 narrative review (PMID 38059379) argues that migraine may involve impaired brain energy metabolism with high adenosine levels, and that aminophylline may relieve pain, particularly post-dural headache. A case report of hemiplegic migraine triggered by regadenoson (an adenosine A2A agonist) indirectly supports the adenosine link.

This reasoning is mechanistic inference. No trial has tested aminophylline in migraine, and the supporting literature consists of a narrative article and case reports.

Other predicted indications (for context):

Predicted Indication	TxGNN Score	Evidence Level	Comment
Migraine with brainstem aura	0.9984	L5	No specific evidence; extrapolated from general migraine
Atrophoderma vermiculata	0.9960	L5	No plausible mechanistic link
Ulerythema ophryogenesis	0.9950	L5	No plausible mechanistic link
Prinzmetal angina	0.9933	L5	Evidence suggests a safety signal (coronary vasospasm), not benefit
Pulmonary hypertension	0.9923	L3	Small, old haemodynamic studies and one Phase 1 safety trial
Sciatic neuropathy	0.9907	L5	One indirect preclinical paper
Hyperthyroidism	0.9906	L4	Literature concerns interactions; potentially harmful
Kyphoscoliotic heart disease	0.9901	L5	Prediction only

Among these, pulmonary hypertension has the most developed evidence base, though it is still modest.

Clinical Trial Evidence

Currently no related clinical trials are registered for migraine disorder.

For reference, the only registered trial found among the other predicted indications was for pulmonary hypertension:

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01530464	Phase 1	Completed	18	Safety, tolerability and pharmacokinetics of oral aminophylline and ambrisentan, alone and combined, in healthy volunteers. Safety study only; no efficacy measured.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
38059379	2023	Review	Pain Management	Proposes migraine is linked to impaired brain energy metabolism and high adenosine; discusses aminophylline as an adenosine antagonist with therapeutic relief in pain, especially post-dural headache
34308528	2022	Case report	J Nucl Cardiol	Hemiplegic migraine triggered by regadenoson (A2A agonist); methylxanthines such as aminophylline reverse its adverse effects
7728647	1995	Case report	Can J Cardiol	Syndrome X patient with an excessive adenosine effect (“myocardial migraine” without ischaemia)
14168418	1964	Review	Aggiornamenti Clinicoterapeutici	Historical article on medical headaches; no abstract available

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
00582662	AMINOPHYLLINE INJ 25MG/ML	Injection (form not recorded)	Not recorded in licence data

Safety Considerations

Drug Interactions: An interaction screen returned 100 potential interactions. The sample reviewed includes:
- Major: Bupropion
- Moderate: Famotidine, ranitidine, cimetidine, nizatidine, doxycycline, tetracycline, minocycline, clarithromycin, hydrocortisone, dexamethasone, betamethasone, triamcinolone, budesonide, obeticholic acid, metreleptin, and several bowel-preparation products (picosulfuric acid, sodium sulfate, polyethylene glycol with electrolytes)
- Minor: Lansoprazole
Signals from the literature (other predicted indications):
- Aminophylline termination of dipyridamole stress triggered coronary vasospasm in variant angina patients.
- Aminophylline increased tremor in hyperthyroid patients, and as a stimulant it may worsen tachycardia in thyrotoxicosis.

Please refer to the package insert for warnings and contraindications, as this information was not available in the compiled data.

Conclusion and Next Steps

Decision: Hold

Rationale: The migraine prediction has a high model score (0.9988) and a plausible adenosine-antagonism rationale, but the evidence is limited to a narrative review, case reports and mechanistic inference, with no registered trials. The Canadian licence record also lacks indication and safety text, so safety screening cannot yet proceed.

To proceed, the following is needed:

Health Canada package insert (warnings, contraindications, approved indications, dosage form) for DIN 00582662
Detailed mechanism of action data
A systematic literature review specific to aminophylline in migraine and post-dural puncture headache
A well-designed controlled trial (or at least a prospective pilot) for migraine
A cardiovascular and drug-interaction risk plan, given the major interaction with bupropion and the vasospasm and tachycardia signals
Separately, if pulmonary hypertension is pursued, controlled efficacy data beyond the small, older haemodynamic studies
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.